Skip to main content
Premium Trial:

Request an Annual Quote

Genomics England Taps Icon to Manage 100K Genomic Data

NEW YORK (GenomeWeb) – Genomics England said today that it has selected Icon, a provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, as its data management partner for the 100,000 Genomes Project.

Specifically, Icon will use its data management capabilities and its clinical trials expertise to validate clinical data from 70,000 cancer and rare disease patients and their families who are participating in the UK-led effort.

"We are very proud that our genomics knowledge and our capabilities in securely managing large clinical and real world datasets have been chosen by Genomics England for such an important and transformative project," Brendan Buckley, Icon's chief medical officer, said in a statement. James Peach, Genomics England's managing director for the 100K Genomes Project main program, added that Icon's expertise in data management "will be fundamental in driving scientific research and accelerating the return of results for NHS patients."

Genomics England also has agreements with a number of bioinformatics companies to provide clinical genome interpretation for the project.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.